对41名患有多重家族性三角上皮瘤的患者中CYLD基因变异的分析
Mengxing Cui1, Liyun Zheng2,3,4, Yue Zhang1
1Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
概括
这项研究在中国患者中发现了6种新的和3种复发的CYLD基因变异,这些患者患有多重家族性三角上皮瘤 (MFT). 这些发现扩大了已知的CYLD基因突变,并有助于为MFT提供遗传咨询.
科学领域:
- 遗传学 是一个遗传学.
- 皮肤病学 皮肤病学
背景情况:
- 多重家族三角瘤 (MFT) 是一种罕见的遗传性疾病.
- CYLD基因与MFT的病变发生有关.
研究的目的:
- 在中国MFT患者中识别CYLD基因变异.
- 建立基因咨询和产前诊断的基础.
- 为了改善MFT干预和患者的治疗结果.
主要方法:
- 采用了全外体测序 (WES) 和全基因组测序 (WGS).
- 桑格测序证实了已识别的变体.
- 迷你基因试验评估了特定变异的功能影响.
主要成果:
- 在41名MFT患者中发现了6种新型和3种复发性致病性CYLD基因变异.
- 临床表现包括鼻子上的斑块或结节.
- 功能分析显示,变体c.1685-9T>G和c.2342-8C>G导致异常的mRNA拼接.
结论:
- 这项研究显著扩大了CYLD基因的突变谱.
- 这些发现对遗传咨询和MFT的管理有着至关重要的意义.
- 它代表了迄今为止在MFT中报告的CYLD基因变异最大的样本大小.
相关概念视频
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
61
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Cystic Fibrosis: Pathogenesis
988
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
988


